Scimitar Equity Issues Analyst Review for Aastrom Biosciences (NASDAQ:ASTM)
Scimitar Equity, LLC has issued a review of Aastrom Biosciences, Inc. (NASDAQ:ASTM) entitled, “New CEO Executes Bold Vision, Financing and Reverse Split with Three Phase 2 Trials Enhancing the Valuation.”
Scimitar initiates with a BUY ranking and maintains that the current momentum and share price appreciation should continue to propel ASTM to its designated valuation given substantial improvements in viability and sustainability associated with the company’s recent financing, reverse split moves, and clinical development activities.
In particular, positive and encouraging RESTORE-CLI Phase 2b interim results have provided a strong signal of the potential efficacy and safety of the company’s autologous cell therapy in patients with critical limb ischemia. ASTM is also planning to announce IMPACT-DCM Phase 2 interim clinical trial results on all 40 patients with 6-month follow-up in Q4 2010. Finally, completion of enrollment in both RESTORE-CLI and IMPACT-DCM positions the company to complete those trials and begin planning for at least one pivotal Phase 3 trial in 2011.
This review is available at website: www.scimitarequity.com.
